Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Bleakley Financial Group LLC

Bleakley Financial Group LLC raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,590 shares of the biopharmaceutical company’s stock after purchasing an additional 375 shares during the period. Bleakley Financial Group LLC’s holdings in Alnylam Pharmaceuticals were worth $610,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Huntington National Bank raised its holdings in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares in the last quarter. Hollencrest Capital Management bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $29,000. R Squared Ltd acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $33,000. Washington Trust Advisors Inc. acquired a new position in Alnylam Pharmaceuticals in the third quarter worth about $42,000. Finally, True Wealth Design LLC raised its stake in Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 153 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 73,964 shares of company stock valued at $20,622,925 in the last quarter. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.7 %

Shares of ALNY stock opened at $276.19 on Monday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The stock has a 50-day simple moving average of $252.78 and a 200 day simple moving average of $262.47. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a market capitalization of $35.62 billion, a P/E ratio of -105.42 and a beta of 0.35.

Analyst Ratings Changes

ALNY has been the subject of several research reports. Sanford C. Bernstein decreased their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research note on Friday, November 1st. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Piper Sandler reaffirmed an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Finally, Chardan Capital reissued a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.